Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer

Cancer Prev Res (Phila). 2022 Dec 1;15(12):791-802. doi: 10.1158/1940-6207.CAPR-22-0106.

Abstract

Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / prevention & control
  • Everolimus / pharmacology
  • Everolimus / therapeutic use
  • Female
  • Humans
  • Mammary Neoplasms, Animal*
  • Mice
  • Receptors, Estrogen / metabolism
  • TOR Serine-Threonine Kinases

Substances

  • Receptors, Estrogen
  • TOR Serine-Threonine Kinases
  • Everolimus
  • MTOR protein, human